<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04041141</url>
  </required_header>
  <id_info>
    <org_study_id>IUSCC-0687</org_study_id>
    <nct_id>NCT04041141</nct_id>
  </id_info>
  <brief_title>Oral Stent Device for Radiation Treatments of Oral Cancers</brief_title>
  <official_title>A Pilot Study Assessing an Oral Stent Device for Radiation Treatments of Oral Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine that ability of the experimental oral stent device to
      reduce the volume of mandible receiving &gt;55 Gy by 50%during radiation treatment as assessed
      duri radiation treatment planning. Patients will have CT scans at three time-points during
      their standard of care radiation treatment. During these visits patients will receive scans
      via CT or cone beam CT scan, with both the standard and experimental oral stent devices.

      During radiation treatment patients will receive the standard oral stent device.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The volume of mandible irradiated to &gt;55 Gy</measure>
    <time_frame>volume irradiated at Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The position of the fiducial marker</measure>
    <time_frame>Change in position at Day 0, Week 3, Week 5</time_frame>
    <description>Fiducial coordinate measured (mm) on XYZ on planning CT</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Tongue Tumor</condition>
  <condition>Tongue Cancer</condition>
  <arm_group>
    <arm_group_label>Oral Cancer</arm_group_label>
    <description>Patients receiving curative radiation treatment for an oral cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT Scan</intervention_name>
    <description>An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)</description>
    <arm_group_label>Oral Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Experimental Oral Stent Device</intervention_name>
    <description>Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place</description>
    <arm_group_label>Oral Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential patients will be identified in the Oncology outpatient clinics or by referrals
        from outside physicians at the Indiana University Simon Cancer Center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥18 year old at the time of informed consent

          -  Ability to provide written informed consent and HIPAA authorization

          -  Accepted for curative radiation treatment of a tongue tumor, either intact or
             postoperatively

          -  Signed consent to study participation

          -  No history of bleeding disorder

          -  Platelets within normal limits (150-450 k/cumm)

        Exclusion Criteria:

          -  History of bleeding disorder

          -  History of allergy to dental grade material
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Langer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Langer, MD</last_name>
    <phone>317-944-2524</phone>
    <email>mlanger@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Miller</last_name>
    <phone>317-278-7614</phone>
    <email>amym@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University Melvin &amp; Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Miller</last_name>
      <phone>317-278-7614</phone>
      <email>amym@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Langer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Mark Langer</investigator_full_name>
    <investigator_title>Professor of Clinical Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>tongue tumor</keyword>
  <keyword>tongue cancer</keyword>
  <keyword>oral cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Tongue Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

